Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.53 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | GGH | Q92820 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259353 | 1.00 | NAALAD2 (0.56) | NAALAD2GAAFOLH1RIMKLASLC1A3 | |
| SCHEMBL5262634 | 0.88 | KMT2A (0.57) | NAALAD2GAASLC1A3MMP9 | |
| SCHEMBL5262631 | 0.88 | KMT2A (0.57) | NAALAD2GAASLC1A3MMP9 | |
| SCHEMBL4654152 | 0.87 | FOLH1 (0.47) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL4654148 | 0.87 | FOLH1 (0.47) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL13610482 | 0.85 | NAALAD2 (0.49) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL31663461 | 0.84 | MMP2 (0.52) | SLC1A3MMP9MMP8 | |
| SCHEMBL21802397 | 0.84 | SLC1A3 (0.54) | GAASLC1A3 | |
| SCHEMBL21802396 | 0.84 | SLC1A3 (0.54) | GAASLC1A3 | |
| SCHEMBL8477195 | 0.82 | FOLH1 (0.50) | NAALAD2GAAFOLH1RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166087-B | Screening agent and use thereof | 恩多塞特公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113166087-A | Shielding agent and application thereof | 恩多塞特公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-2322515-B1 | A process for the preparation of an N-carboxy amino acid anhydride or an amino acid carbamate | JSR CORP (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-8748650-B2 | Method for production of N-carboxy amino acid anhydride and amino acid carbamate compound | JSR CORPORATION (JP) | 2014-06-10 | — | — | US | disclosed |
| CN-102123994-A | N-carboxy amino acid anhydride and amino acid carbamate compound production method | JSR CORP | 2011-07-13 | — | — | CN | disclosed |
| US-20110152561-A1 | METHOD FOR PRODUCTION OF N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND | JSR CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2322515-A1 | N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND PRODUCTION METHOD | JSR Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| CN-101327226-A | Light-emitting microorganisms and cells for tumour diagnosis/therapy | GENELUX CORP (US) | 2008-12-24 | — | — | CN | disclosed |
| CN-100415897-C | Microorganisms and cells for the diagnosis and treatment of tumors | GENELUX GMBH (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-0979292-A2 | GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY | ZENECA LIMITED (GB) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998051787-A2 | GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY | ZENECA LIMITED (GB) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | NAALAD2 69/4885GAA 2087/4885FOLH1 1171/4885 |
| US-20110152561-A1 | METHOD FOR PRODUCTION OF N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND | CA7, CPS1, DNPEP | NAALAD2 31/4885GAA 1560/4885FOLH1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.